aprotinin + calcium chloride + human fibrinogen + human thrombin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
aprotinin + calcium chloride + human fibrinogen + human thrombin: clinical details
Prescribing considerations
- Restrict use to experienced surgeons trained in product preparation and application.
- Use only as an adjunct when standard surgical techniques are insufficient; it does not replace control of brisk arterial or venous bleeding or skin sutures.
- Apply only to the intended topical surface and protect surrounding tissues from unwanted adhesion.
- Carefully assess previous exposure to aprotinin and allergy to bovine proteins because repeat exposure may increase anaphylaxis risk.
- Record the product name and batch number for traceability.
- Paediatric safety and effectiveness have not been established.
Contraindications and cautions
- Intravascular application.
- Known hypersensitivity to any component, including aprotinin.
- Use alone for active or spurting arterial or venous bleeding uncontrolled by conventional techniques.
- Use as a replacement for skin sutures.
Monitoring
- During spray application, monitor blood pressure, pulse, oxygen saturation and end-tidal carbon dioxide for possible air or gas embolism.
- Observe for hypersensitivity; stop application and initiate emergency management at the first sign of a reaction.
- Assess for compressive effects when applied in confined anatomical spaces.
- Ensure the prepared solutions are appropriately thawed, visually acceptable and used with compatible equipment.
Clinical pharmacology
The two-component system reproduces the final stage of coagulation: thrombin converts fibrinogen to fibrin, calcium supports clot stabilisation, and aprotinin inhibits premature fibrinolysis. The solidified sealant is degraded by fibrinolysis and phagocytosis.
Formulation and product differences
- Supplied frozen as two separate solutions within a single-use double-chamber syringe.
- One chamber contains human fibrinogen with synthetic aprotinin; the other contains human thrombin with calcium chloride.
- The components combine in equal volumes through the joining piece and application cannula.
- Available pack volumes differ; not all pack sizes may be marketed.
aprotinin + calcium chloride + human fibrinogen + human thrombin interactions
Formal interaction studies have not been performed; the most important issues are local incompatibilities at the application site.
Alcohol-, iodine- or heavy-metal-containing antiseptics
Residues may denature the protein components and reduce sealant performance, so they should be removed as far as possible before application.
Oxidised cellulose preparations
These may reduce the sealant's effectiveness and should not be used as carrier materials.
Other medicinal products
The sealant must not be mixed directly with other medicinal products.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.